RSCM
SWTX

Rock Springs Capital Management’s SpringWorks Therapeutics SWTX Stock Holding History

Rock Springs Capital Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-328,911
Closed -$11.9M – 108
2024
Q4 		$11.9M Buy
328,911
+129,056
+65% +$4.51M 0.45% 57
2024
Q3 		$6.4M Hold
199,855
– – 0.21% 76
2024
Q2 		$7.53M Buy
+199,855
New +$8.41M 0.23% 74

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rock Springs Capital Management's SWTX Position: Q1 2025 in Review

Rock Springs Capital Management sold out of SpringWorks Therapeutics (SWTX) in Q1 2025, closing a stake of 328,911 shares — an estimated $11.9M sold.

Rock Springs Capital Management first reported a position in SWTX in Q2 2024 and held it in 3 quarters. The position peaked at $11.9M in Q4 2024. 306 funds tracked by Wall St. Rank hold SWTX as of Q1 2025.

  • Rock Springs Capital Management reported no remaining SpringWorks Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Rock Springs Capital Management sold 328,911 SpringWorks Therapeutics shares in Q1 2025, an estimated $11.9M.
  • Rock Springs Capital Management first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 3 quarters.
  • Rock Springs Capital Management's SpringWorks Therapeutics position peaked at $11.9M in Q4 2024.
  • 306 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2025.

Based on Rock Springs Capital Management's 13F filing for Q1 2025, filed 15 May 2025.